---
document_datetime: 2025-11-23 08:02:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rilonacept-regeneron.html
document_name: rilonacept-regeneron.html
version: success
processing_time: 0.117163
conversion_datetime: 2025-12-24 17:16:49.622183
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rilonacept Regeneron (previously Arcalyst)

[RSS](/en/individual-human-medicine.xml/66964)

##### Withdrawn

This medicine's authorisation has been withdrawn

rilonacept

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Rilonacept Regeneron](#more-information-on-rilonacept-regeneron-834)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 23 October 2009 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Rilonacept Regeneron (Rilonacept). Rilonacept Regeneron was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS).

The marketing authorisation holder (MAH) responsible for Rilonacept Regeneron was Regeneron UK Limited. The European Commission was notified by letter dated 20 September 2012 of the MAH's decision to voluntarily withdraw the marketing authorisation for Rilonacept Regeneron for commercial reasons. The product had never been placed on the market in any country of the European Community.

On 24 October 2012 the European Commission issued a decision to withdraw the marketing authorisation for Rilonacept Regeneron.

Pursuant to this decision the European Public Assessment Report for Rilonacept Regeneron is updated to reflect the fact that the marketing authorisation is no longer valid.

Rilonacept Regeneron : EPAR - Summary for the public

English (EN) (720.83 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 24/09/2010

[View](/en/documents/overview/rilonacept-regeneron-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-377)

български (BG) (431.73 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/bg/documents/overview/rilonacept-regeneron-epar-summary-public_bg.pdf)

español (ES) (558.31 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/es/documents/overview/rilonacept-regeneron-epar-summary-public_es.pdf)

čeština (CS) (610.22 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/cs/documents/overview/rilonacept-regeneron-epar-summary-public_cs.pdf)

dansk (DA) (560.46 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/da/documents/overview/rilonacept-regeneron-epar-summary-public_da.pdf)

Deutsch (DE) (562.4 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/de/documents/overview/rilonacept-regeneron-epar-summary-public_de.pdf)

eesti keel (ET) (557.77 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/et/documents/overview/rilonacept-regeneron-epar-summary-public_et.pdf)

ελληνικά (EL) (706.33 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/el/documents/overview/rilonacept-regeneron-epar-summary-public_el.pdf)

français (FR) (582.58 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/fr/documents/overview/rilonacept-regeneron-epar-summary-public_fr.pdf)

italiano (IT) (562.61 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/it/documents/overview/rilonacept-regeneron-epar-summary-public_it.pdf)

latviešu valoda (LV) (639.76 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/lv/documents/overview/rilonacept-regeneron-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (590.52 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/lt/documents/overview/rilonacept-regeneron-epar-summary-public_lt.pdf)

magyar (HU) (611.12 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/hu/documents/overview/rilonacept-regeneron-epar-summary-public_hu.pdf)

Malti (MT) (660 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/mt/documents/overview/rilonacept-regeneron-epar-summary-public_mt.pdf)

Nederlands (NL) (558.55 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/nl/documents/overview/rilonacept-regeneron-epar-summary-public_nl.pdf)

polski (PL) (620.09 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/pl/documents/overview/rilonacept-regeneron-epar-summary-public_pl.pdf)

português (PT) (559.21 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/pt/documents/overview/rilonacept-regeneron-epar-summary-public_pt.pdf)

română (RO) (588.46 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/ro/documents/overview/rilonacept-regeneron-epar-summary-public_ro.pdf)

slovenčina (SK) (616.19 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/sk/documents/overview/rilonacept-regeneron-epar-summary-public_sk.pdf)

slovenščina (SL) (497.45 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/sl/documents/overview/rilonacept-regeneron-epar-summary-public_sl.pdf)

Suomi (FI) (560.01 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/fi/documents/overview/rilonacept-regeneron-epar-summary-public_fi.pdf)

svenska (SV) (558.39 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/sv/documents/overview/rilonacept-regeneron-epar-summary-public_sv.pdf)

## Product information

Rilonacept Regeneron : EPAR - Product Information

English (EN) (493.5 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 24/09/2012

[View](/en/documents/product-information/rilonacept-regeneron-epar-product-information_en.pdf)

[Other languages (23)](#file-language-dropdown-280)

български (BG) (1.47 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/bg/documents/product-information/rilonacept-regeneron-epar-product-information_bg.pdf)

español (ES) (773.42 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/es/documents/product-information/rilonacept-regeneron-epar-product-information_es.pdf)

čeština (CS) (1.14 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/cs/documents/product-information/rilonacept-regeneron-epar-product-information_cs.pdf)

dansk (DA) (787.15 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/da/documents/product-information/rilonacept-regeneron-epar-product-information_da.pdf)

Deutsch (DE) (779.06 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/de/documents/product-information/rilonacept-regeneron-epar-product-information_de.pdf)

eesti keel (ET) (745.84 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/et/documents/product-information/rilonacept-regeneron-epar-product-information_et.pdf)

ελληνικά (EL) (1.61 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/el/documents/product-information/rilonacept-regeneron-epar-product-information_el.pdf)

français (FR) (807.27 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/fr/documents/product-information/rilonacept-regeneron-epar-product-information_fr.pdf)

íslenska (IS) (485.37 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/is/documents/product-information/rilonacept-regeneron-epar-product-information_is.pdf)

italiano (IT) (754.21 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/it/documents/product-information/rilonacept-regeneron-epar-product-information_it.pdf)

latviešu valoda (LV) (1.25 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/lv/documents/product-information/rilonacept-regeneron-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.03 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/lt/documents/product-information/rilonacept-regeneron-epar-product-information_lt.pdf)

magyar (HU) (1.19 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/hu/documents/product-information/rilonacept-regeneron-epar-product-information_hu.pdf)

Malti (MT) (1.14 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/mt/documents/product-information/rilonacept-regeneron-epar-product-information_mt.pdf)

Nederlands (NL) (771.71 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/nl/documents/product-information/rilonacept-regeneron-epar-product-information_nl.pdf)

norsk (NO) (521.03 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/no/documents/product-information/rilonacept-regeneron-epar-product-information_no.pdf)

polski (PL) (1.21 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/pl/documents/product-information/rilonacept-regeneron-epar-product-information_pl.pdf)

português (PT) (800.2 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/pt/documents/product-information/rilonacept-regeneron-epar-product-information_pt.pdf)

română (RO) (1018.64 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/ro/documents/product-information/rilonacept-regeneron-epar-product-information_ro.pdf)

slovenčina (SK) (1.1 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/sk/documents/product-information/rilonacept-regeneron-epar-product-information_sk.pdf)

slovenščina (SL) (1.12 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/sl/documents/product-information/rilonacept-regeneron-epar-product-information_sl.pdf)

Suomi (FI) (808.8 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/fi/documents/product-information/rilonacept-regeneron-epar-product-information_fi.pdf)

svenska (SV) (777.01 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2012

[View](/sv/documents/product-information/rilonacept-regeneron-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** S/0006 28/06/2012

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rilonacept Regeneron: EPAR - All Authorised presentations

English (EN) (217.77 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 24/09/2010

[View](/en/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-511)

български (BG) (308.08 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/bg/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_bg.pdf)

español (ES) (431.7 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/es/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_es.pdf)

čeština (CS) (509.78 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/cs/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (431.7 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/da/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (472.64 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/de/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (431.7 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/et/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (515.27 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/el/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_el.pdf)

français (FR) (431.9 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/fr/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (431.17 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/it/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (511.32 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/lv/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (498.69 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/lt/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (509.98 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/hu/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (512.66 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/mt/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (431.33 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/nl/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_nl.pdf)

polski (PL) (514.07 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/pl/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_pl.pdf)

português (PT) (431.94 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/pt/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_pt.pdf)

română (RO) (497.95 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/ro/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (510.77 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/sk/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (476.32 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/sl/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (431.55 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/fi/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (432.23 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

24/09/2010

[View](/sv/documents/all-authorised-presentations/rilonacept-regeneron-epar-all-authorised-presentations_sv.pdf)

Rilonacept Regeneron: EPAR - Conditions imposed on member states for safe and effective use - Annex IV

English (EN) (117.54 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 12/11/2009

[View](/en/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_en.pdf)

[Other languages (21)](#file-language-dropdown-0)

български (BG) (384.73 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/bg/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_bg.pdf)

español (ES) (294.12 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/es/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_es.pdf)

čeština (CS) (364.49 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/cs/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_cs.pdf)

dansk (DA) (250.98 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/da/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_da.pdf)

Deutsch (DE) (296.06 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/de/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_de.pdf)

eesti keel (ET) (291.4 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/et/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_et.pdf)

ελληνικά (EL) (317.47 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/el/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_el.pdf)

français (FR) (250.84 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/fr/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fr.pdf)

italiano (IT) (292.89 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/it/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_it.pdf)

latviešu valoda (LV) (371.02 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/lv/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lv.pdf)

lietuvių kalba (LT) (354.89 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/lt/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_lt.pdf)

magyar (HU) (295.96 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/hu/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_hu.pdf)

Malti (MT) (311.88 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/mt/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_mt.pdf)

Nederlands (NL) (296.29 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/nl/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_nl.pdf)

polski (PL) (309.36 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/pl/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pl.pdf)

português (PT) (310.3 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/pt/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_pt.pdf)

română (RO) (357.59 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/ro/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_ro.pdf)

slovenčina (SK) (309.75 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/sk/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sk.pdf)

slovenščina (SL) (301.29 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/sl/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sl.pdf)

Suomi (FI) (292.15 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/fi/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_fi.pdf)

svenska (SV) (250.29 KB - PDF)

**First published:**

12/11/2009

**Last updated:**

12/11/2009

[View](/sv/documents/conditions-member-states/rilonacept-regeneron-epar-conditions-imposed-member-states-safe-and-effective-use-annex-iv_sv.pdf)

## Product details

Name of medicine Rilonacept Regeneron (previously Arcalyst) Active substance rilonacept International non-proprietary name (INN) or common name rilonacept Therapeutic area (MeSH) Cryopyrin-Associated Periodic Syndromes Anatomical therapeutic chemical (ATC) code L04AC08

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Rilonacept Regeneron is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) with severe symptoms, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), in adults and children aged 12 years and older.

## Authorisation details

EMA product number EMEA/H/C/001047

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

Regeneron UK Limited

40 Bank Street

Marketing authorisation issued 23/10/2009 Withdrawal of marketing authorisation 24/10/2012 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rilonacept Regeneron : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (287.01 KB - PDF)

**First published:** 06/07/2010

**Last updated:** 24/09/2012

[View](/en/documents/procedural-steps-after/rilonacept-regeneron-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Arcalyst

Adopted

Reference Number: EMEA/CHMP/346815/2009

English (EN) (76.79 KB - PDF)

**First published:** 23/07/2009

**Last updated:** 23/07/2009

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-arcalyst_en.pdf)

## Initial marketing authorisation documents

Rilonacept Regeneron : EPAR - Public assessment report

English (EN) (2.33 MB - PDF)

**First published:** 12/11/2009

**Last updated:** 12/11/2009

[View](/en/documents/assessment-report/rilonacept-regeneron-epar-public-assessment-report_en.pdf)

#### More information on Rilonacept Regeneron

This product was originally designated an [orphan medicine](/en/medicines/human/orphan-designations/eu-3-07-456) on 10 July 2007. Rilonacept Regeneron was withdrawn from the Community register of orphan medicinal products by the European Commission in October 2012 at the time of the withdrawal of the marketing authorisation.

**This page was last updated on** 30/10/2012

## Share this page

[Back to top](#main-content)